- Investing Ideas
- Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
5
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
5 companies
Galderma Group
Market Cap: CHF 38.6b
Operates as a dermatology company worldwide.
GALD
CHF 164.40
7D
3.8%
1Y
47.0%
Sandoz Group
Market Cap: CHF 27.2b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 62.90
7D
-2.9%
1Y
49.2%
Bachem Holding
Market Cap: CHF 5.3b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 71.00
7D
-10.9%
1Y
42.5%
Tecan Group
Market Cap: CHF 2.0b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 156.80
7D
5.2%
1Y
-0.8%
Basilea Pharmaceutica
Market Cap: CHF 614.8m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 49.60
7D
-7.5%
1Y
8.3%